June 1, 2021
On the heels of the temporary supply halt of Yoshindo/Teijin Pharma’s Enbrel (etanercept) biosimilar products, market leader Ayumi Pharmaceutical said on May 31 that it is restricting the shipment of its versions in anticipation of a flood of orders. The...read more